Opinion|Videos|October 18, 2024
Biomarker Discovery and Exploration for SCLC
Key Takeaways
- Biomarker testing in SCLC is essential for personalizing treatment, though less established than in non-small cell lung cancer.
- Testing is usually incorporated at diagnosis or during disease progression to guide therapeutic decisions.
Panelists discuss how biomarker testing is currently utilized in the management of patients with small cell lung cancer (SCLC), including its timing within the treatment journey, while also exploring the existing unmet needs in biomarker testing for SCLC and potential strategies to address and overcome these challenges in the future.
Advertisement
Episodes in this series
What is the role of biomarker testing in your patients with small cell lung cancer (SCLC)? When in their treatment journey do you incorporate it?
What are the current unmet needs with biomarker testing in SCLC, and how can they be addressed and overcome in the future?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
GLP-1 Therapies in 2026: Beyond Blood Sugar and the Scale
2
What ADA 2026 Data Reveal About the Growing Gap in Ketone Monitoring: Eden Miller, DO
3
ACA Enrollment Erosion Deepens After Open Enrollment Ends
4
Efgartigimod Effective in Broad Subsets of Patients With gMG
5